Related references
Note: Only part of the references are listed.Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain
Ingrid I. van Gameren et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A. Dispenzieri et al.
LEUKEMIA (2009)
Diego)
Angela Dispenzieri et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis
Tilmann Bochtler et al.
HAEMATOLOGICA (2008)
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
Ashutosh D. Wechalekar et al.
HAEMATOLOGICA (2008)
Long-term outcome-of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
Vaishali Sanchorawala et al.
BLOOD (2007)
Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response
Morie A. Gertz et al.
HAEMATOLOGICA (2007)
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2007)
Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65
David C. Seldin et al.
BLOOD (2006)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
A Dispenzieri et al.
BLOOD (2006)
Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis
H Akar et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2005)
Amyloidosis: Diagnosis and management
Morie A. Gertz et al.
CLINICAL LYMPHOMA & MYELOMA (2005)
Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis
V Sanchorawala et al.
BONE MARROW TRANSPLANTATION (2005)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis
M Matsuda et al.
INTERNAL MEDICINE (2005)
Diagnostic performance of quantitative κ and λ free light chain assays in clinical practice
JA Katzmann et al.
CLINICAL CHEMISTRY (2005)
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
G Palladini et al.
BLOOD (2004)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy
HJ Lachmann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Quantitative analysis of serum free light chains - A new marker for the diagnostic evaluation of primary systemic amyloidosis
RS Abraham et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2003)
Stem cell transplantation for the management of primary systemic amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF MEDICINE (2002)
Share Paper
